Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:32 ET | 21389 | 1.23 |
09:33 ET | 6626 | 1.2501 |
09:35 ET | 2302 | 1.25 |
09:39 ET | 2500 | 1.241 |
09:44 ET | 750 | 1.26 |
09:46 ET | 1500 | 1.28 |
09:48 ET | 7134 | 1.27 |
09:50 ET | 4000 | 1.27 |
09:51 ET | 19106 | 1.28 |
09:53 ET | 6606 | 1.31 |
09:55 ET | 2910 | 1.31 |
09:57 ET | 5754 | 1.305 |
10:00 ET | 380 | 1.31 |
10:04 ET | 1125 | 1.3 |
10:06 ET | 165 | 1.315 |
10:08 ET | 9023 | 1.2893 |
10:09 ET | 650 | 1.2747 |
10:13 ET | 500 | 1.2701 |
10:15 ET | 3000 | 1.272 |
10:18 ET | 13300 | 1.28 |
10:20 ET | 1800 | 1.28 |
10:24 ET | 200 | 1.27 |
10:26 ET | 2100 | 1.26 |
10:27 ET | 675 | 1.2498 |
10:29 ET | 1000 | 1.2499 |
10:33 ET | 1000 | 1.2142 |
10:38 ET | 333 | 1.2471 |
10:42 ET | 785 | 1.2499 |
10:45 ET | 1267 | 1.23 |
10:47 ET | 14800 | 1.1969 |
10:49 ET | 2900 | 1.199 |
10:51 ET | 1900 | 1.2 |
10:54 ET | 5100 | 1.1999 |
10:56 ET | 250 | 1.2242 |
10:58 ET | 400 | 1.215 |
11:00 ET | 670 | 1.23 |
11:02 ET | 2100 | 1.225 |
11:05 ET | 2632 | 1.2001 |
11:09 ET | 100 | 1.2001 |
11:14 ET | 1257 | 1.2 |
11:20 ET | 1303 | 1.2278 |
11:21 ET | 6191 | 1.22 |
11:23 ET | 650 | 1.1984 |
11:30 ET | 500 | 1.1805 |
11:32 ET | 200 | 1.19 |
11:34 ET | 336 | 1.1899 |
11:36 ET | 822 | 1.19 |
11:38 ET | 1900 | 1.19 |
11:43 ET | 3030 | 1.205 |
11:45 ET | 1500 | 1.1901 |
11:48 ET | 1000 | 1.1913 |
11:52 ET | 1400 | 1.2 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 40.5M | -0.5x | --- |
Moleculin Biotech Inc | 35.5M | -1.4x | --- |
Sio Gene Therapies Inc | 33.1M | -0.7x | --- |
Cadrenal Therapeutics Inc | 32.9M | 0.0x | --- |
Coeptis Therapeutics Holdings Inc | 32.3M | 12.9x | --- |
Odonate Therapeutics Inc | 48.6M | -0.6x | --- |
Equillium, Inc. is a clinical-stage biotechnology company develops novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The Company’s initial product candidate, itolizumab (EQ001), is a clinical-stage monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The Company’s pipeline is focused on developing EQ001, EQ101 and EQ102 disease modifying treatments for multiple severe immuno-inflammatory disorders. Its clinical development programs for EQ001 for the treatment of acute graft-versus-host disease (aGVHD) and lupus/lupus nephritis. The Company is in the process of clinical development of EQ101 and EQ102 and to initiate a Phase II study of EQ101 in alopecia areata and a Phase I study of EQ102 in celiac disease. The Company is conducting the EQUATE study, is a Phase Ib clinical study of EQ001 therapy concomitant with steroids for the treatment of aGVHD.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $40.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 34.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $-2.34 |
Book Value | $2.26 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.